Get the Stockscreener App
9.90
2.89%
-0.25
Oruka Therapeutics Inc stock is traded at $9.90, with a volume of 86,841.
It is down -2.89% in the last 24 hours and down -28.05% over the past month.
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$10.15
Open:
$10.16
24h Volume:
86,841
Relative Volume:
0.29
Market Cap:
$346.31M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.24%
1M Performance:
-28.05%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.77
$10.89
1-Week Range:
$9.53
$11.03
52-Week Range:
$9.53
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
9.90 | 346.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.83 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.93 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.15 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.59 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock - MarketBeat
Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock - MarketBeat
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock - Investing.com Canada
Oruka Therapeutics sees $1.41 million in stock purchases by Venrock Healthcare - Investing.com
Oruka Therapeutics (ORKA) to Release Earnings on Thursday - Defense World
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewswire
Can This Clinical-Stage Biotech's March Conference Circuit Signal Major Developments? - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Financial Fitness Check: Examining Oruka Therapeutics Inc (ORKA)’s Key Ratios - The Dwinnex
Oruka Therapeutics Inc (ORKA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpTime to Buy? - MarketBeat
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Wolfe Research Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wolfe Research - Defense World
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat
Oruka Therapeutics (ORKA) Projected to Post Earnings on Thursday - Defense World
Abio Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arca Biopharma, Inc. Is Fair to Shareholders - ACCESS Newswire
Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17 - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Time to Sell? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week LowWhat's Next? - MarketBeat
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket - Benzinga
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8%Should You Sell? - MarketBeat
Geode Capital Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year LowWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8%What's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) versus Myriad Genetics (NASDAQ:MYGN) Head to Head Comparison - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week LowShould You Sell? - MarketBeat
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):